Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | AKT2 | P31751 | 1/20 | 0.61 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.61 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9208171 | 0.84 | AKT1 (0.72) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL282714 | 0.84 | AKT1 (1.00) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL299526 | 0.83 | AKT1 (0.71) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL11891722 | 0.82 | AKT1 (0.57) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL10108709 | 0.81 | AKT1 (0.68) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL288427 | 0.81 | AKT1 (1.00) | AKT1MEN1TSHRKMT2ACA1 | |
| SCHEMBL2196395 | 0.80 | AKT1 (0.67) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL10108708 | 0.80 | AKT1 (0.63) | AKT1MEN1TSHRKMT2APDPK1 | |
| SCHEMBL9720507 | 0.80 | CA1 (0.60) | AKT1MEN1TSHRKMT2ACA1 | |
| SCHEMBL14864417 | 0.79 | AKT1 (0.65) | AKT1MEN1TSHRKMT2APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648255-B2 | Inhibitors for treatment of hematological malignancies | MASARYKOVA UNIVERZITA (CZ) | 2023-05-16 | — | — | US | disclosed |
| EP-2428504-B1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | UNIV TEXAS (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| US-8962663-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130184317-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-07-18 | — | — | US | disclosed |
| US-8420678-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. | 2012-07-26 | — | — | US | disclosed |
| EP-2428504-A1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | The Board of Regents of the University of Texas System (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2009129267-A2 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | AKT1 92/4885MEN1 1607/4885TSHR 4193/4885 |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | AKT1 92/4885MEN1 1607/4885TSHR 4193/4885 |
| US-20130184317-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | AKT1 92/4885MEN1 1607/4885TSHR 4193/4885 |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEC, PLEKHA1 | AKT1 80/4885MEN1 955/4885TSHR 3939/4885 |
| US-11648255-B2 | Inhibitors for treatment of hematological malignancies | GAB1, BTK, MCL1 | AKT1 1250/4885MEN1 1850/4885TSHR 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.